A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

By Massarweh Suleiman  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 819-827

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

By Esteva Francisco   Moulder Stacy   Gonzalez-Angulo Ana   Ensor Joe   Murray James   Green Marjorie   Koenig Kimberly   Lee Mong-Hong   Hortobagyi Gabriel   Yeung Sai-Ching  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 63-72

Springer Publishing Company

Access to resources Recommend Favorite

Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

By Kurosumi Masafumi   Takatsuka Yuichi   Watanabe Toru   Imoto Shigeru   Inaji Hideo   Tsuda Hitoshi   Akiyama Futoshi   Sakamoto Goi   Ikeda Tadashi   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 6, 2008-06 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

By Bernsdorf Mogens  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 463-470

Springer Publishing Company

Access to resources Recommend Favorite